GE HealthCare Technologies (GEHC) investor relations material

Business performance and financial outlook

• Guidance for the year was reduced due to significant inflationary pressures, particularly from freight, logistics, and memory chip costs, totaling around $250 million each for tariffs and inflation over two years.

• Despite these headwinds, EPS is still expected to grow mid to high single digits this year, with cost initiatives and pricing actions set to yield greater benefits in 2027.

• Order growth was 1% in Q1 against a tough 10% comp, with expectations for accelerating order growth and mid-single digit sales growth over the midterm.

• Gross margins are expected to improve in the second half of the year due to seasonality, new product launches, and reduced tariff impact.

• Capital deployment priorities are reinvestment in the business, targeted M&A, and ongoing share buybacks, with recent buybacks executed at perceived value prices.

Strategic initiatives and business structure

• Advanced Imaging Solutions (AIS) was formed by combining AVS and AIS to better align with customer needs and enable horizontal solutions leveraging data and AI.

• PCS business is under strategic review due to lower margins and performance, with improvement plans underway and a focus on evaluating its role within the company.

• The Heartbeat management system is driving lean operations, improved sales execution, and margin enhancement.

Innovation and product pipeline

• Over $3 billion invested since the spin is fueling a robust innovation cycle, with 10 new products launching across all modalities over the next 6–18 months.

• Photon counting CT is positioned as a new market opportunity, with a sales funnel exceeding $100 million and revenue contributions expected from 2026–2027.

• New products like Vivid Pioneer are outperforming internal estimates and contributing to order and backlog growth.